John Theurer Cancer Center at Hackensack University Medical Center Study Tracks Long-Term Survival With First-Line Nivolumab Plus Ipilimumab in Patients With Advanced Non-Small-Cell Lung Cancer   

John Theurer Cancer Center at Hackensack University Medical Center Study Tracks Long-Term Survival With First-Line Nivolumab Plus Ipilimumab in Patients With Advanced Non-Small-Cell Lung Cancer

Pooled analysis deepens clinical benefit knowledge and assesses survival impact

A recent study in the Annals of Oncology provided greater understanding of the clinical benefit of first-line nivolumab plus ipilimumab (NIVO + IPI), which prolongs survival versus chemotherapy in advanced non-small-cell lung cancer (NSCLC), in a large pooled patient population. 

  • Durable responses and long-term survival benefits were observed across histologies/PD-L1 expression levels.
  • Patients who showed a 1L NIVO + IPI treatment response at 6 months experienced improved post-landmark survival benefit.
  • Responders with higher tumor burden reduction from baseline derived long-term overall survival benefit.

In this study, researchers pooled analyses of four 1L NIVO + IPI studies supporting the regimen’s efficacy for advanced NSCLC treatment. They assessed overall survival, progression-free survival, objective response rate, duration of response and safety. Landmark analyses of overall survival by response status at 6 months and by tumor burden reduction in responders to NIVO + IPI also were assessed.

The outcomes observed in this large patient population further support this first-line treatment option for advanced NSCLC.

Learn more about innovations in cancer treatments at Hackensack University Medical Center.

We use cookies to improve your experience. Please read our Privacy Policy or click Accept.
X